Filing Flows › NeuroPace (NPCE) › Recalls, complaints & regulation
NeuroPace (NPCE): clinical trials
NeuroPace (NPCE) beyond its filings: 2 active clinical trials.
NeuroPace's latest quarter
NeuroPace, Q2 2026: revenue $22.8M (+17% year over year), operating margin -22.5%, net loss $6.2M, operating cash flow −$3.9M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does NeuroPace have?
2 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.